Abstract:ETHNOPHARMACOLOGICAL RELEVANCE:Dengzhan Shengmai capsule (DZSM) is a traditional herb medicine used by Dai, an ethnic-minority community living in Xishuang banna tropical rainforest in Southwest of China. It was originally intended to treat disorders caused by insufficient brain function, characterized by gibberish, unresponsiveness, or confusion. Accumulating clinical evidences exhibited that it is effective on treating ischemic stroke (IS). However, the action of DZSM against IS needs to be further elucidated.AIM OF THE STUDY:To investigate the effect of DZSM and its active components against IS and the way of its action by multi-omics and network pharmacology.MATERIALS AND METHODS:A middle cerebral artery occlusion/reperfusion (MCAO/R) rat model was established to investigate the effect of DZSM on the focal cerebral ischemia/reperfusion injury. An integrated strategy combining metabolomics, network pharmacology and transcriptomics was performed to systematically clarify the underlying mechanism of action of DZSM against IS. AutoDock Vina was applied to conduct molecular docking simulation for the binding between the potential active compounds and targets. Arachidonic acid (AA) induced platelet aggregation and lipopolysaccharide (LPS) stimulated microglial cells BV2 inflammation models were applied for the in vitro validation of effects of DZSM and its potential active compounds.RESULTS:In MCAO/R rats, DZSM could significantly reduce the infarct volume. Putative target prediction and functional enrichment analysis based on network pharmacological indicated that the key targets and the potential active compounds played important roles in DZSM's treatment to IS. The targets included four common genes (PTGS1, PTGS2, NFKB1 and NR1I2) and five key TFs (NFKB1, RELA, HIF1A, ESR1 and HDAC1), whilst 22 potential active compounds were identified. Molecular docking indicated that good binding affinity have been seen between those compounds and NR1I2, NFKB1, and RELA. Multi-omics study revealed that DZSM could regulate glutamate by influencing citrate cycle and glutamate involved pathways, and have showed neuroprotection activity and anti-inflammation activity by inhibiting NF-κB pathway. Neuroprotective effects of DZSM was validated by regulating of NF-κB signaling pathway and its downstream NO, TNF-α and IL-6 cytokines contributed to the activity of DZSM and its active compounds of scutellarin, quercetin 3-O-glucuronide, ginsenoside Rb1, schizandrol A and 3, 5-diCQA, whilst the antithrombotic activity of DZSM and its active compounds of schisanhenol, apigenin and schisantherin B were screened out by anti-platelet aggregation experiment.CONCLUSION:DZSM could against IS via regulating its downstream NO, TNF-α and IL-6 cytokines through NF-κB signaling pathway and alleviating thrombosis.

EZH2 Inhibitor DZNep Modulates Microglial Activation and Protects Against Ischaemic Brain Injury after Experimental Stroke.

Abstract P759: Microglial EZH2 Inhibition Leads to Neuroprotection After Stroke in Aged Mice

Abstract 16: Inhibiting Ezh2 Is Neuroprotective After Stroke In Aged Mice

Histone methyltransferase enzyme enhancer of zeste homolog 2 counteracts ischemic brain injury via H3K27me3‐mediated regulation of PI3K/AKT/mTOR signaling pathway

Hippo/MST1 Signaling Mediates Microglial Activation Following Acute Cerebral Ischemia–reperfusion Injury

Inhibition Of Histone Deacetylase 3 By Mir-494 Alleviates Neuronal Loss And Improves Neurological Recovery In Experimental Stroke

Silencing of microRNA-494 inhibits the neurotoxic Th1 shift via regulating HDAC2-STAT4 cascade in ischaemic stroke

Ezetimibe Attenuates Oxidative Stress and Neuroinflammation Via the AMPK/Nrf2/TXNIP Pathway after MCAO in Rats.

Multi-omics Integrated Analysis of the Protective Effect of EZH2 inhibition in Mice with Renal Ischemia-Reperfusion Injury

AZD1390, an ataxia telangiectasia mutated inhibitor, attenuates microglia‐mediated neuroinflammation and ischemic brain injury

Upregulation of EphA4 deteriorate brain damage by shifting microglia M1-polarization via NF-κB signaling after focal cerebral ischemia in rats

Arresting the bad seed: HDAC3 regulates proliferation of different microglia after ischemic stroke

PLXNA2 knockdown promotes M2 microglia polarization through mTOR/STAT3 signaling to improve functional recovery in rats after cerebral ischemia/reperfusion injury

A Novel SIRT6 Activator Ameliorates Neuroinflammation and Ischemic Brain Injury Via EZH2/FOXC1 Axis

Ezetimibe attenuates functional impairment via inhibition of oxidative stress and inflammation in traumatic spinal cord injury.

Enhancer of Zeste Homolog 2 Modulates Oxidative Stress‐mediated Pyroptosis in Vitro and in a Mouse Kidney Ischemia‐reperfusion Injury Model

EZH2 plays a crucial role in ischemia/reperfusion-induced acute kidney injury by regulating p38 signaling

EZH2 Mediates miR-146a-5p/HIF-1α to Alleviate Inflammation and Glycolysis after Acute Spinal Cord Injury

The NEDD8-activating enzyme inhibitor MLN4924 reduces ischemic brain injury in mice

Multi-omics and Network Pharmacology Study Reveals the Effects of Dengzhan Shengmai Capsule Against Neuroinflammatory Injury and Thrombosis Induced by Ischemic Stroke.

A novel compound DBZ ameliorates neuroinflammation in LPS-stimulated microglia and ischemic stroke rats: Role of Akt(Ser473)/GSK3β(Ser9)-mediated Nrf2 activation